Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ZOVIRAX DUAL Rx/OTC STATUS SUGGESTED

This article was originally published in The Tan Sheet

Executive Summary

ZOVIRAX DUAL Rx/OTC STATUS SUGGESTED as a way of maintaining insurance coverage for the medication in April 29 comments by the American Medical Women's Association supporting the switch of the orally administered genital herpes drug. Indicating that increased cost to patients of an OTC version of Zovirax (acyclovir) may be an issue in the switch process, AMWA President Kathryn Bemmann, MD, suggested that "Medicaid and insurance coverage for the medication...be continued for individuals who are currently using 'covered' prescriptions." She added that "perhaps a dual status of OTC and Rx could be maintained."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082769

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel